Fort Lauderdale, Fla., March 15, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- MediXall Group Inc., (OTCQB: MDXL), a technology and innovation-driven organization structured to bring effective change to the U.S. Healthcare Industry, is pleased to announce today the expansion of its strategic advisory board with the appointment of clinical pharmacist and scientific liaison Ellis A. Ellis. Dr. Ellis’ distinguished career includes work with the Department Health Services (DHS) Medi-Cal Drug Formulary, compliance consultant, process efficiency expert and published author of original research related to drug to drug interactions. As an Advisor, Dr. Ellis will provide guidance and support on strategic initiatives as the company accelerates business growth, expands its services, and strives to increase market share.
“We’re thrilled to have Dr. Ellis join our Advisory Board,” said Michael Swartz, President of MediXall. “His illustrious 30-year career in pharmacy and hospital management will be a valuable resource for our team as we continue to expand our prescription drug benefits and streamline efficiency with our platform overall. To take advantage of the opportunity we have with MediXall Rx, we have named Henry Solano the project lead.”
For more than a decade Dr. Ellis has served as a clinical pharmacist for Orange County Global Medical Center. In this role, he’s performed initial dosing and adjustments for antibiotics, performed clinical interventions and has been a consultant for physicians regarding medication formulary selection, renal dosing adjustments, side effects, and the monitoring and dose adjustments for all antibiotics, H2, low molecular weight heparin (LMWH), heparin, and Coumadin. In addition, Dr. Ellis is a senior supervising pharmacist for technicians and power of attorney for the ordering of Schedule II narcotics. His extensive experience in pharmaceuticals has provided continuous support while developing and launching the MediXallRx Prescription Discount program. The MediXall Rx Savings Card is accepted nationwide and savings of up to 75 percent can be applied to prescription medications.
Dr. Ellis, who is licensed in Arizona, California, and Florida, was previously the lead scientific liaison on several products included in the Department Health Services (DHS) Medi-Cal Drug Formulary. He coordinated the development and promulgation of DHS policies. For the administration and reimbursement of drug-related programs and services, he analyzed legislation, made recommendations, prepared cost containment proposals, and served as a consultant for critical issues with DHS.
"The MediXall platform fills a void in the healthcare industry by providing consumers and providers with price transparency and ease of use for everything from scheduling appointments to filling prescriptions,” said Dr. Ellis A. Ellis. “I’m pleased to join its board, where I plan to lend my expertise on all matters, especially those related to prescription drugs, dosing, and compliance.”
Additional accomplishments include: lead advisor to hospitals, in which he developed quality assurance pharmacy programs; consulting pharmacist for Skilled Nurses Facilities; publication and instruction on formulary antibiotic algorithm; published paper on drug to drug interactions in Title 22 facilities; centralized eight hospital healthcare systems for LTC pharmacy organization; served as an expert witness to Long Beach and Los Angeles District Attorneys’ Offices; and achieved an estimated cost saving to a hospital organization of $500,000 year over year. Dr. Ellis is a member of the American Health System Pharmacist Association.
As a member of the board, Dr. Ellis will work closely with the MediXall leadership team to consult on business strategy and sales, marketing, and product plans; as well as provide guidance on the implementation of the MediXallRx Discount program. With the launch of the MediXallRx Discount Program, MediXall.com provides a powerful, free tool to search and compare prescription drug prices, which can differ greatly between competing pharmacies. The program and MediXallRx Saving Card offer consumers immediate savings on both generic and brand prescription medications.
For more information, please visit www.medixallgroup.com or call (954) 440-4678.
About MediXall.com: Medixall.com is a new generation healthcare marketplace platform designed to address the growing need of self-pay and high deductible consumers for greater transparency and price competition in their healthcare costs. With MediXall, consumers now have the option to search for doctors or dentists and book appointments based on cost, distance, ratings, and availability at the click of a button. By delivering a solution that better connects consumers with high-quality healthcare providers and wellness services, MediXall.com enables healthcare providers to engage consumers with a level of price transparency and digital convenience that they have come to expect in every other aspect of their lives. In this era of rapidly increasing deductibles and healthcare costs, the cloud-based platform is designed to be transformational and disruptive to traditional methods of medical care and provisioning of medical services to the consumer. For more information, please visit www.medixallgroup.com or call (954) 440-4678.
About MediXall Group, Inc.: MediXall Group is a technology and innovation-driven organization purposefully designed and structured to bring effective change to the U.S. healthcare industry that is actively trading on the OTCQB under the symbol “MDXL.” The Company believes its revolutionary approach will help drive much-needed change that it envisions is needed in the current healthcare system. The mission of the MediXall Group is to revolutionize the medical industry by improving communication; providing better technology and support services; and enabling more efficient, cost-effective healthcare for the consumer. By approaching the healthcare ecosystem as a whole, MediXall creates, invests and incubates companies that embody its mission statement.
Safe Harbor Statement: This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company’s current plans and expectations, as well as future results of operations and financial condition. Specifically, the Company’s ability to raise additional capital, execute its business plan and strategy, sustain or increase gross margins, achieve profitability and build shareholder value are forward-looking statements. A more extensive listing of risks and factors that may affect the Company’s business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the Company with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.